A patient being treated with Aduro Biotech's (Nasdaq: ADRO) CRS-207 developed listeriosis. The stock price plunged $5.09 to $27.14.
Aduro Biotech patient develops listeriosis
November 24, 2015 at 12:04 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.